Thrombosis Research
Volume 125, Issue 3 , Pages 216-219 , March 2010

The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease

  • Adam L. Cohen

      Affiliations

    • Department of Internal Medicine, Banner Good Samaritan Medical Center, Phoenix, Arizona, USA
    • Corresponding Author InformationCorresponding author. Department of Oncology, Huntsman Cancer Institute, 2000 Circle of Hope, Suite 2100, Salt Lake City, UT 84112.
    • ,
  • Rami Sarid

      Affiliations

    • Department of Oncology, Phoenix VA Health Care System, Phoenix, Arizona, USA

Received 10 November 2008 ,Revised 2 January 2009 ,Accepted 10 January 2009.

References 

  1. Goldhaber SZ. Pulmonary embolism. N Engl J Med. 1998;339:93–104
  2. Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death: The changing mortality in hospitalized patients. JAMA. 1986;255:2039–2042
  3. Shorr AF. The pharmacoeconomics of deep vein thrombosis treatment. Am J Med. 2007;120:S35–41
  4. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007;7:307–315
  5. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis following monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood. 2008;112:3582–3586
  6. Palumbo A, Rajkumar SJ, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423
  7. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic Disease. Cancer. 2004;101:558–566
  8. Sallah S, Huasian A, Wan J, Vos P, Nguyen NP. The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol. 2004;15:1490–1494
  9. Righini M, Boehlen F, Gueddi S, Le Gal D, de Moerloose P. Extensive thromboembolic event as initial presentation of monoclonal gammopathy of indetermined significance. Thromb Haemost. 2006;96:93–94
  10. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the international myeloma working group. Br J Haemotol. 2003;121:749–757
  11. Keren DF. Coagulation disorders in patients with monoclonal gammopathies. Hematol Oncol Clin North Am. 1993;7:1153–1159
  12. Disdier P, Swiader L, Aillaud M, Boucraut J, Harlé JR, Weiller PJ. IgM monoclonal gammopathy, lymphoid proliferations, and lupus anticoagulant. Am J Med. 1997;102:319–320
  13. Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med. 1983;101:545–552
  14. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van ES LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med. 1978;65:607–613
  15. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. Jan 2008;19(1):135–140
  16. Northrup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol. 2006;101:1524–1528
  17. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. May 2008;111:4902–4907
  18. Kyle RA, Therneau TM, Rajmukar SV. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The original Mayo Clinic series 25 tears later. Mayo Clin Proc. 2004;79:859–866

PII: S0049-3848(09)00026-7

doi: 10.1016/j.thromres.2009.01.004

Thrombosis Research
Volume 125, Issue 3 , Pages 216-219 , March 2010

Article Tools